Literature DB >> 34773368

T-cell surface generation of dual bivalent, bispecific T-cell engaging, RNA duplex cross-linked antibodies (dbBiTERs) for re-directed tumor cell lysis.

Maciej Kujawski1, Lin Li1, Harry Li1, Paul J Yazaki1, Piotr Swiderski2, John E Shively1.   

Abstract

BACKGROUND: Genetic engineered Bispecific T-cell engagers (BiTEs) generate potent cytotoxic effects.
METHODS: Alternately, click chemistry engineered, dual specific bivalent Bispecific T-cell engaging antibodies (dbBiTEs) on T-cell surfaces can be generated from parent monoclonal antibodies.
RESULTS: We show the formation of dbBiTEs on the surface of T-cells along with the introduction of complementary 2'-OMe RNA 32-mer oligonucleotides allowing duplex formation between antibodies, designated as dbBiTERs. dbBiTERs generated in solution from anti-CEA and anti-CD3 OKT3 antibodies retained specific binding to CEA positive versus CEA negative cancer cells and to CD3 positive T-cells comparable to dbBiTEs. When T-cells were precoated with dbBiTEs or dbBiTERs and mixed with CEA positive versus CEA negative cancer cells, similar dose dependent and specific cytotoxicity were observed in redirected cell lysis assays. On-cell generated dbBiTERs exerted potent cytotoxic responses against CEA positive targets and were localized at the cell surface by immuno-gold EM. In addition, we demonstrate that target and T-cells, each coated separately with complementary 2'OMe-RNA-linked antibodies can be cross-linked by RNA duplex formation in vitro to generate redirected cell lysis.
CONCLUSION: The facile generation of dbBiTERs with specific cytolytic activity from intact antibodies and their generation on-cell offers a new avenue for antigen specific T-cell therapy.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  BiTE; CEA; T-cell therapy; bispecific antibody; click chemistry

Mesh:

Substances:

Year:  2021        PMID: 34773368      PMCID: PMC9177045          DOI: 10.1002/biot.202100389

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   5.726


  38 in total

1.  DNA-based hybridization chain reaction for amplified bioelectronic signal and ultrasensitive detection of proteins.

Authors:  Bing Zhang; Bingqian Liu; Dianping Tang; Reinhard Niessner; Guonan Chen; Dietmar Knopp
Journal:  Anal Chem       Date:  2012-06-05       Impact factor: 6.986

2.  Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.

Authors:  Ursula Reusch; Magesh Sundaram; Pamela A Davol; Sarah D Olson; James B Davis; Kurt Demel; Julie Nissim; Ritesh Rathore; Paul Y Liu; Lawrence G Lum
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 3.  Engineering therapeutic bispecific antibodies using CrossMab technology.

Authors:  Christian Klein; Wolfgang Schaefer; Joerg T Regula; Charles Dumontet; Ulrich Brinkmann; Marina Bacac; Pablo Umaña
Journal:  Methods       Date:  2018-11-16       Impact factor: 3.608

4.  Nanogold-based bio-bar codes for label-free immunosensing of proteins coupling with an in situ DNA-based hybridization chain reaction.

Authors:  Jun Zhou; Mingdi Xu; Dianping Tang; Zhuangqiang Gao; Juan Tang; Guonan Chen
Journal:  Chem Commun (Camb)       Date:  2012-12-28       Impact factor: 6.222

5.  A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.

Authors:  Brian M Zeglis; Kuntal K Sevak; Thomas Reiner; Priya Mohindra; Sean D Carlin; Pat Zanzonico; Ralph Weissleder; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-05-24       Impact factor: 10.057

6.  Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.

Authors:  Pamela A Davol; Janelle A Smith; Nicola Kouttab; Gerald J Elfenbein; Lawrence G Lum
Journal:  Clin Prostate Cancer       Date:  2004-09

Review 7.  Affinity and avidity in antibody-based tumor targeting.

Authors:  Stephen I Rudnick; Gregory P Adams
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

Review 8.  Click Chemistry as a Tool for Cell Engineering and Drug Delivery.

Authors:  Yukiya Takayama; Kosuke Kusamori; Makiya Nishikawa
Journal:  Molecules       Date:  2019-01-04       Impact factor: 4.411

9.  Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.

Authors:  Maciej Kujawski; Lin Li; Supriyo Bhattacharya; Patty Wong; Wen-Hui Lee; Lindsay Williams; Harry Li; Junie Chea; Kofi Poku; Nicole Bowles; Nagarajan Vaidehi; Paul Yazaki; John E Shively
Journal:  BMC Cancer       Date:  2019-09-05       Impact factor: 4.430

10.  Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice.

Authors:  Raffaella Rossin; Ron M Versteegen; Jeremy Wu; Alisher Khasanov; Hans J Wessels; Erik J Steenbergen; Wolter Ten Hoeve; Henk M Janssen; Arthur H A M van Onzen; Peter J Hudson; Marc S Robillard
Journal:  Nat Commun       Date:  2018-05-04       Impact factor: 14.919

View more
  1 in total

Review 1.  Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.

Authors:  Hongyu Zhang; Zhenyu Wu; Deyu Hu; Min Yan; Jing Sun; Jiejuan Lai; Lianhua Bai
Journal:  Vaccines (Basel)       Date:  2022-06-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.